7517-CL-1101
A Phase 1/2, Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Known to Express WT1 Antigen
Condition: Advanced solids tumors known to Express WT1 Tumor Antigen (Melanoma, Ovarian, Colorectal) | Last Updated: 3 Jun 22 | Status:
View Full Study
